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Abstract
Angiotensin (Ang) II mediates pathophysiologial changes in the kidney. Ang-(1–7) by interacting with the G protein-coupled
receptor Mas may also have important biological activities.
In this study, renal deficiency for Mas diminished renal damage in models of renal insufficiency as unilateral ureteral
obstruction and ischemia/reperfusion injury while the infusion of Ang-(1–7) to wild-type mice pronounced the pathological
outcome by aggravating the inflammatory response. Mas deficiency inhibited NF-kB activation and thus the elevation of
inflammation-stimulating cytokines, while Ang-(1–7) infusion had proinflammatory properties in experimental models of
renal failure as well as under basal conditions. The Ang-(1–7)-mediated NF-kB activation was Mas dependent but did not
involve Ang II receptors. Therefore, the blockade of the NF-kB-activating properties of the receptor Mas could be a new
strategy in the therapy of failing kidney.
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Introduction
Patients with chronic kidney diseases (CKD) represent a
worldwide problem. The prevalence of CKD in the US population
is around 11%, and because of the increase in diabetes, obesity
and hypertension an exponential increase is predicted for the next
decade [1,2].
The activation of the renal renin angiotensin system (RAS),
characterized by elevated ACE expression and increased local
angiotensin (Ang) II production, has been found in many human
kidney diseases [3]. Ang II, the main peptide of RAS, is a true
cytokine that regulates cell growth, inflammation and fibrosis and
therefore contributes to renal damage progression [4]. Blockade of
Ang II actions, by ACE inhibitors or AT1 antagonists, is one of the
current therapeutic strategies with proven beneficial effects in the
treatment of chronic renal diseases [5,6].
Besides Ang II, other Ang peptides, such as Ang IV [Ang-(3–8)]
and Ang-(1–7) may also have important biological activities [7].
Especially, Ang-(1–7) has become an angiotensin of interest in the
past few years, since its cardiovascular and baroreflex actions
counteract those of Ang II [8]. Studies from our group and others in
mice deficient for the G protein-coupled receptor Mas and cell
transfection experiments gave evidence that Mas codes for a
functional Ang-(1–7) receptor [9,10], that is expressed predomi-
nantly in testis and in distinct areas of fore-brain such as the
hippocampus and amygdada and, less strongly but detectable, in
kidney and heart [11]. First suggestions that the Mas gene codes for
an Ang II-sensitive receptor [12] have been corrected by findings
that alterations in intracellular Ca2+-concentrations in Mas-trans-
fected cells after Ang II treatment could only be confirmed in cells
expressing the Ang II receptor AT1 endogenously [13,14].
Mice deficient for the Mas protooncogene present a sustained
long-term potentiation in hippocampal neurons and sex-specific
alterations in exploratory behaviour [15] and heart rate and blood
pressure variability were observed [16].
Results
Disease evolution in Mas-deficient mice following
unilateral ureteral obstruction
The unilateral ureteral obstruction (UUO) model is character-
ized by interstitial inflammatory cell infiltration, NF-kB activation,
apoptosis and fibrosis [17]. Many studies have demonstrated that
Ang II, via AT1 or AT2 receptors, contributes to renal damage
following UUO [18–19].
As Ang-(1–7) has been shown to have protective cardiovascular
effects [21,22] and this heptapeptide has been also described to
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have effects in the kidney [23,24], we investigated effects of
deficiency in the Mas receptor associated to Ang-(1–7) signaling in
the UUOmodel. Thus, UUOwas performed inMas-knockout mice
(Mas2/2) and their wild-type controls (Mas+/+) and kidneys were
studied after 2, 5 and 7 days. The contralateral kidneys of Mas-
deficient animals showed no histological alterations and did not differ
from contralateral wild-type kidneys. Masson staining of kidney
sections two days after UUO showed occasional perivascular
mononuclear cell infiltrates and tubular damage in wild-type
kidneys, congruent to our previous description [18], while obstructed
kidneys lacking Mas showed no inflammatory infiltrates and tubular
lesions (Figure 1A, lower panel). Wild-type UUO kidneys
revealed prominent perivascular, interstitial matrix deposition that
was less pronounced in Mas2/2 mice (Figure 1B, blue staining).
This difference further increased at the endpoint of 7 days, when
wild-type kidneys showed pronounced infiltration of cells in the
interstitium and fibrosis while much less stained cells in the knockout
kidneys were detectable (Figure 1C). Notably, the UUO kidneys
with Mas receptors showed occasional glomerular collapse (arrow-
heads) that was not observed in kidneys lacking the receptor
(Figure 1C). Glomerular pathology was quantified by counting the
glomeruli with pathomorphological lesions such as collapse, matrix
deposition, microthrombi and cellular infiltrates. The number of
glomeruli with pathomorphological changes was significantly less in
Mas-deficient UUO kidneys than in kidneys of wild-type mice after 5
days of UUO (Figure 1D).
Importantly, the significant less renal damage after UUO in
Mas-deficient mice led also to a preserved renal function compared
to wild-type mice with UUO. Blood urea nitrogen (BUN)
(Figure 1E) and urea (data not shown) were significant less in
mice with Mas deficiency two days after UUO. Notably, under
sham conditions both strains did not differ in renal function (data
not shown).
Since these results suggested that the absence of the receptor
Mas prevents renal disease progression in the UUO model, we
next examined the expression of apoptosis-related proteins that
promote (Bax) or protect (Bcl-xL) from cell death. Two days after
UUO, the Bax/Bcl-xL ratio increased in the obstructed kidneys of
both genotypes in comparison to the contra-lateral control kidneys
but significantly less in Mas-deficient mice. This less pronounced
increase in the Bax/Bcl-xL ratio in UUO-kidneys of Mas2/2
mice implicated induction of less apoptosis (Figure 1F).
To dissect the inflammatory response in this model, we
examined inflammatory cell infiltration by immunohistochemistry
with a specific anti-F4/80 antibody that recognizes murine
monocytes/macrophages. In control samples and in non-injured
kidneys of both genotypes, only few cells were positive for F4/80
(data not shown). Two and five days after UUO, obstructed
kidneys of Mas+/+ mice showed scattered infiltrates of mononu-
clear cells within interstitial spaces focally distributed mainly at
juxtamedular level, compared to contralateral kidneys
(Figure 1G; Figure 1H, upper panels). Obstructed kidneys
of Mas-deficient mice lacked this pronounced increase in
infiltrating cells (Figure 1G; Figure 1H, lower panels). After
7 days of UUO, the presence of monocytes/macrophages
infiltrates in Mas-deficient kidneys was significantly lower than
in obstructed wild-type kidneys (Figure 1G; Figure 1H, right
panels). This clearly supports our data that renal Mas deficiency
retards UUO damage progression.
Ang-(1–7) worsens the renal lesions following unilateral
ureteral obstruction
If the beneficial effects of Mas deficiency were related to the
lacking interaction of Ang-(1–7) with its signaling-associated
receptor, detrimental effects of the heptapeptide via Mas on the
UUO-initiated pathology in wild-type mice had to be anticipated.
Therefore, UUO was performed in two groups of wild-type mice,
one receiving Ang-(1–7) through a subcutaneously placed mini-
pump, the other one saline. While Mas deficiency reduced the
induction of changes in the ratio of pro-/anti-apoptotic proteins in
obstructed kidneys (Figure 1F), the infusion of Ang-(1–7)
significantly pronounced apoptotic processes (Figure 2A). This
detrimental effect was already manifest at the second day post
surgery and even more significant after 5 days.
Histological evaluation identified in UUO kidneys of Ang-(1–7)-
treated wild-type mice an increase in matrix deposition in the
mesangial area (blue staining) in comparison to obstructed kidneys
of the saline-treated animals (Figure 2B). The number of
glomeruli with pathomorphological changes was significantly
more in UUO kidneys of mice treated with Ang-(1–7) than in
kidneys of saline-treated animals after 5 days of UUO (UUO wild-
type saline: 5.760.8 glomeruli with pathomorphological changes
per HPF and UUO wild-type Ang-(1–7): 9.962.0 glomeruli with
pathomorphological changes per HPF; P,0.05).
To investigate whether the more severe phenotype related to an
Ang-(1–7) infusion led also to more pronounced inflammation,
F4/80-positive cells were stained (exemplarily shown for the
medulla in Figure 2C). The saline group showed only occasional
infiltration of inflammatory cells within interstitial areas (arrow-
heads). However, there was a marked increase of mononuclear
cells in interstitial area in the Ang-(1–7)-infused group implicating
more inflammation. This pronounced inflammation was also
supported by quantitative analysis counting infiltrating leukocytes.
The UUO kidneys of mice that received Ang-(1–7) showed
significantly more leukocyte infiltration than the UUO kidneys
from the saline treated animals (Figure 2D).
To follow the hypothesis that Mas deficiency prevents, and Ang-
(1–7) stimulates inflammation we next checked for NF-kB
activation. UUO significantly increased renal NF-kB activity in
saline-treated and Mas-wildtype mice (obstructed vs. contralateral
kidney). Confirming our immunohistological data, this activation
was even more pronounced by Ang-(1–7) treatment but signifi-
cantly reduced in mice lacking the Mas receptor (Figure 2E and
F).
NF-kB is a pivotal transcription factor in chronic immune and
inflammatory diseases [25,26]. In human kidney diseases elevated
renal NF-kB activity correlates with upregulation of proinflam-
matory parameters [3,25–27]. Although there are no current data
in humans, many experimental models have shown that NF-kB
blockade (by different maneuvers, including IkB overexpression,
NF-kB decoy oligonucleotides, NF-kB inhibitors, ACE inhibition,
statins, glucocorticoids and antioxidants) attenuates renal inflam-
mation [4,18,26].
We recently described for the UUO model that two different
NF-kB inhibitors, PDTC and parthenolide, diminished the
inflammatory cell infiltration and downregulated gene expression
of several proinflammatory factors [18]. Thus, we further
investigated whether NF-kB downstream signaling was also
influenced by alterations in the Ang-(1–7)/Mas axis. Obstructed
kidneys of wildtype mice showed increased mRNA expression of
proinflammatory cytokines (TNF-a, IL-6), and chemokines (MCP-
1) compared to the contralateral ones (Figure 2G) as previously
described [18]. Ang-(1–7) infusion further increased IL-6 and
MCP-1 mRNA concentrations, while in Mas-deficient mice,
obstructed kidneys presented significant less gene activation
compared to Mas-wildtype mice, both at 2 and 5 days
(Figure 2G). Thus, the combination of results taken from
immunohistochemistry and molecular biological techniques con-
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sistently proves that Ang-(1–7) is a proinflammatory peptide whose
actions are abrogated in the absence of the receptor Mas.
Impact of Mas and Ang-(1–7) on renal ischemia/
reperfusion injury
Following these results in the UUO model, we set out to
investigate whether the effects on NF-kB regulation by Ang-(1–7)
and Mas are restricted to the UUO model or also act in other
models of renal inflammation. We thus introduced a second
experimental kidney model that is characterized by an inflamma-
tory component. Since renal ischemia is a major cause of acute
and end-stage renal failure [28], producing serious morbidity and
mortality, renal ischemia/reperfusion (I/R) injury was chosen to
evaluate whether Ang-(1–7) and Mas was involved in the primary
mechanisms determining ischemia-mediated renal failure.
In wild-type animals (I/R saline and I/R Mas+/+), renal
ischemia/reperfusion led to diffuse matrix deposition as well as
partial glomerular collapse 3 days after reperfusion (Figure 3A
and B, first and third panels). Furthermore, reduced glomerular
perfusion was detected (Figure 3B, first and third panels).
Compared to these findings, I/R kidneys of mice infused with
Ang-(1–7) showed more dramatic tissue destruction as character-
ized by marked infiltrates of mixed inflammatory cells and more
severe diffuse matrix deposition (Figure 3A and B, second panel).
These kidneys were also characterized by intraglomerular protein
precipitates (arrowheads), increased cellularity, and more reduced
glomerular perfusion in glomerular capillaries (Figure 3B, second
panel). In contrast to the more severe pathomorphological changes
in the I/R-Ang-(1–7) group, Mas-deficient kidneys showed no
evidence of matrix deposition in the renal parenchyma 3 days post
ischemia. Notably, there were also significant less structural
changes in the glomeruli (Figure 3A and B, forth panel). The
protective effect of Mas deficiency was also illustrated by the
number of glomeruli with pathomorphological changes. The
number of altered glomeruli was significantly more in I/R kidneys
of mice treated with Ang-(1–7) than in kidneys of saline-treated
animals after 3 days of I/R (I/R wild-type saline: 2.860.3
glomeruli with pathomorphological changes per HPF and I/R
wild-type Ang-(1–7): 4.360.4 glomeruli with pathomorphological
changes per HPF; P,0.01), whereas it was less in Mas-deficient
kidneys compared to their wild-type (I/R wild-type: 4.360.4
glomeruli with pathomorphological changes per HPF and I/R
knockout: 2.360.3 glomeruli with pathomorphological changes
per HPF; P,0.001).
Next, the number of infiltrating leukocytes has been calculated.
In I/R kidneys from Ang-(1–7)-treated mice the number of
infiltrating leukocytes was significantly more than counted in I/R
kidneys from wild-type mice treated with saline (Figure 3C). In
contrast, in kidneys from Mas-deficient mice the number of
infiltrating leukocytes was less than one quarter of that counted in
I/R kidneys from their wild-type controls (Figure 3C).
As in the UUO model, Ang-(1–7) infusion increased renal NF-
kB activation in comparison to the I/R kidneys of saline-infused
animals (Figure 3D and E). This was paralleled by significant
higher mRNA levels of the proinflammatory cytokines MCP1 and
IL-6 (Figure 3F). In contrast, the strong beneficial impact of the
lack of the Mas receptor on I/R-induced pathomorphological
changes was congruent with less NF-kB activation and significant
lower renal mRNA of cytokines with proinflammatory properties
(Figure 3D–F).
Systemic infusion of Ang-(1–7) into healthy mice induces
renal inflammation requiring the Mas receptor
To evaluate whether the proinflammatory effects of Ang-(1–7)
are depending on a predisposition in failing kidney due to the
pathophysiological stimulus or whether elevated circulating Ang-
(1–7) concentrations induce renal inflammation already under
basal conditions, we administered the heptapeptide to healthy
wild-type mice. Systemic minipump infusion of Ang-(1–7) into
normal control mice for 5 days caused an important increase in
the number of monocytes/macrophages in the interstitium,
distributed in a focal manner (Figure 4A, upper row). This
heptapeptide-mediated increase was completely blocked by co-
infusion with A779, an Ang-(1–7) receptor antagonist (Figure 4A,
upper row), or in Mas-deficient mice. In kidneys of the latter one
there were no infiltrating cells detectable, showing similar staining
than in saline-infused mice (Figure 4A, second row). These results
clearly demonstrate the proinflammatory properties of Ang-(1–7)
under physiological conditions and that the presence of inflam-
matory cells in kidneys of animals infused with Ang-(1–7) requires
the Mas receptor (Figure 4B).
Since there is controversy on the impact of the Ang II receptors
AT1 (in rodents two isoforms: AT1A and AT1B) and AT2 on
Ang-(1–7)-mediated signaling [7,8], we used recently generated
mice deficient in all three Ang II receptors (triple knockout, TKO)
and their wild-type controls (triple wildtype, TWT) [29] to
evaluate whether the proinflammatory properties of Ang-(1–7)
depend on the expression of Ang II receptors. In both, TKO and
TWT, infusion of Ang-(1–7) induces the presence of inflammatory
cells, without differences between genotypes, showing that this
effect is AT1 and AT2 independent (Figure 4A, third and lower
row, Figure 4B). Notably, the observed effect that A779
treatment significantly diminishes inflammatory cells in Ang-(1–
7)-infused wild-type mice was still preserved in mice deficient for
all three Ang II receptors.
Figure 1. Evolution of renal lesions in the model of unilateral ureteral obstruction (UUO) in Mas-deficient and wild-type mice. UUO
was set in Mas-deficient (Mas2/2) mice and their wild-type controls (Mas+/+), and animals were studied after 2, 5 and 7 days; Masson staining (A)
and Azan blue (B) after 2 days and Masson staining after 7 days (C), respectively; magnification: 1006, 2006and 1006, respectively. (D) Shows the
quantification of glomeruli with pathomorphological lesions such as collapse, matrix deposition, microthrombi and cellular infiltrates, in UUO kidneys
of Mas-deficient mice and their wild-type controls. (E) Demonstrates lower concentrations of blood urea nitrogen in Mas-deficient mice 2 days after
UUO. (F) Shows evaluation of apoptosis-related proteins at 2 days of UUO. Data of renal Bax/Bcl-xl ratio expressed as n-fold of increase vs.
contralateral kidneys of each genotype, expressed as mean6SEM of 6–8 animals per group. Open and black bars represent Mas+/+ or Mas2/2,
respectively; C: contralateral, O: obstructed kidneys; * P,0.05 vs. contralateral kidney of its own genotype; # P,0.05 vs. Mas+/+ obstructed kidney.
(G) Shows the computer analysis of monocytes/macrophages scoring 2, 5 and 7 days of UUO. The presence of inflammatory cell infiltration was
determined by immunohistochemistry with anti-F4/80 antibody (specific for monocytes/macrophages; brown staining); magnification: 2006. There
were no differences between the number of monocytes/macrophages in contralateral kidneys at 2, 5 and 7 days of UUO (data not shown). Results
are expressed as F4/80 positive cells/mm2 as mean6SEM of 6–10 animals per group. Open bars show data of Mas +/+ and black bars of Mas2/2
kidneys, * P,0.05 vs. contralateral kidney of the same genotype; # P,0.05 vs. Mas+/+ obstructed kidneys; 1 P,0.05 vs. Mas+/+ mice. (H) Illustrates
inflammatory cell infiltration in obstructed kidneys (cortex) of Mas+/+ and Mas2/2 mice (representative kidneys of 6–10 studied in each genotype,
each time point).
doi:10.1371/journal.pone.0005406.g001
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Figure 3. Impact of Mas and Ang-(1–7) on renal lesions in the model of ischemia/reperfusion (I/R). I/R was performed in wild-type mice
infused with saline (I/R Saline) or Ang-(1–7) (I/R Ang-(1–7)) and in mice deficient for Mas (I/R Mas2/2) and their wild-type controls (I/R Mas+/+).
Animals were studied 3 days after I/R. Figures A and B show Ladewig and PAS staining respectively of group-representing renal sections.
Magnification: 4006. (C) Infiltrating leukocytes were counted based on their morphology and location within renal cortex, medulla, and pelvis in mice
infused with saline or Ang-(1–7) and in wild-type (Mas+/+) and Mas-deficient mice (Mas2/2). Renal NF-kB activity after I/R was measured by EMSA
(D) and calculated (E) as renal NF-kB activity expressed as n-fold increase vs. wild-type controls and shown as mean6SEM of 6–10 animals per group
analyzed in duplicate. ¥ P,0.05 vs. saline-infused mice; # P,0.05 vs. Mas+/+ mice. The right diagram (F) shows mRNA levels of MCP-1 and IL-6
expressed as n-fold increase vs. wild-type controls and expressed as mean6SEM of 6–8 animals per group analyzed in duplicate. ¥ P,0.05 vs. saline-
infused mice; # P,0.05 vs. Mas+/+ mice.
doi:10.1371/journal.pone.0005406.g003
Figure 2. Effect of Ang-(1–7) treatment on apoptosis, fibrosis and inflammatory processes in wild-type mice with unilateral ureteral
obstruction (UUO). Wild-type mice underwent UUO and were treated with Ang-(1–7) or saline (systemic infusion by osmotic minipumps). (A) A
representative western blot showing renal Bax and Bcl-xL expression (upper panel) and the calculation of the Bax/Bcl-xl ratio (lower panel) after 5
days of UUO. Open and black bars represent data of saline- or Ang-(1–7)-infused mice, respectively, expressed as mean6SEM of 6 animals per group.
Figures B and C show representative kidney sections (B: cortex with glomerulus; C: medulla) with van Gieson staining and anti-F4/80
immunostaining, respectively (positive immunoreactivity reveals brown signal [arrowheads]). Magnification: 4006. (D) Infiltrating leukocytes were
counted based on their morphology and location within renal cortex, medulla, and pelvis in mice infused with saline or Ang-(1–7). (E) Renal NF-kB
activation was measured in wild-type mice infused with saline or Ang-(1–7) and in Mas-deficient mice (Mas2/2) and their respective wild-type
controls (Mas+/+) at 2 and 5 days of UUO. The figure shows data of renal NF-kB activity expressed as n-fold increase vs. contralateral kidney as
mean6SEM of 6 animals per group analyzed in duplicate. (F) Shows a representative EMSA experiment. Competition assay with a 100-fold excess of
unlabeled NF-kB shows the specificity of the binding (marked by arrows). The position of free oligonucleotides is indicated. (G) Shows data of gene
expression of proinflammatory factors (MCP-1 and IL-6) obtained by real-time PCR experiments and expressed as n-fold increase vs. contralateral
kidney as mean6SEM of 8–10 animals per group; C: contralateral, O: obstructed kidneys. * P,0.05 vs. contralateral kidney of the same genotype; #
P,0.05 vs. Mas+/+ obstructed kidney; ¥ P,0.05 vs. saline-infused obstructed kidneys.
doi:10.1371/journal.pone.0005406.g002
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Figure 4. Angiotensin-(1–7) induces inflammatory cell infiltration under physiological conditions. Mas-deficient mice (Mas2/2) and
mice deficient in all three Ang II receptors (AT1A, AT1B and AT2 = TKO) and their wild-type controls (Mas+/+ and TWT) were infused with Ang-(1–7) or
saline for 5 days. Part of the Ang-(1–7)-infused mice were co-treated with the specific Ang-(1–7)-antagonist A779. A shows representative kidney
slices stained by anti F4/80 antibody of each group and B summarizes the computer analysis of the monocytes/macrophages score. Results are
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Figure 5. Ang-(1–7) induces nuclear localization of p65 and p50 and proinflammatory cytokines in cultured mouse tubuloepithelial
cells. (A) Growth arrested cells were treated with 1027 mol/L Ang-(1–7) and AngII for 1 hour and p65 and p50 subunits were detected by an indirect
immunostaining using a mouse FITC-labeled secondary antibody (green staining). Nuclei were stained with propidium iodure (in red). In the merge,
the yellow staining shows nuclear localization of the NF-kB proteins after Ang-(1–7) stimulation. The results are representative of 3 independent
observations done by confocal microscopy. (B) Growth arrested cells were incubated with 1027 mol/L Ang-(1–7), AngII or TNFa for 1 hour. Thereafter,
nuclear extracts were isolated and NF-kB activity was determined by binding assay with a labeled NF-kB oligonucleotide and analyzed by EMSA. Data
are expressed as an n-fold increase vs. control cells, as mean6SEM of 4 experiments. *P,0.05 vs. control. (C) Growth arrested cells were stimulated
with 1027 mol/L Ang-(1–7) or TNFa for 18 and 24 hours. Gene expression of MCP-1 and IL-6 was analyzed by real-time PCR. Results are expressed as
mean6SEM of 4 experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0005406.g005
expressed as F4/80 positive cells/mm2 as mean6SEM of 6–10 animals per group. (C) NF-kB data of densitometric analysis of EMSA experiments
expressed as mean6SEM of 6–10 animals per group analyzed in duplicate were performed in all 4 investigated genotypes under the three different
treatment regimes. *P,0.05 vs. saline-infused of each genotype, # P,0.05 vs Ang-(1–7)-infused Mas+/+. P,0.05 vs. Ang-(1–7)-infused TWT. y
P,0.05 vs. Ang-(1–7)-infused TKO.
doi:10.1371/journal.pone.0005406.g004
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Activation of renal NF-kB by angiotensin-(1–7) infusion
requires the Mas receptor
To link the increased staining of F4/80-positive cells after Ang-
(1–7) infusion to molecular mechanisms, NF-kB activation was
detected in the kidneys of the investigated groups. Systemic
infusion of Ang-(1–7) for 5 days increased NF-kB DNA-binding
activity in the kidney of wild-type mice (Mas+/+ and TWT)
(Figure 4C) and stimulated release of proinflammatory cytokines
(data not shown). Congruent with the immunohistochemical
findings, there was no increase in renal NF-kB activity in Mas
knockout mice infused with Ang-(1–7). Pharmacological blockade
of Mas by treatment with A779 significantly diminished renal NF-
kB activation in response to Ang-(1–7) infusion in wild-type strains
(Figure 4C). Together, our findings provide robust proof that
Ang-(1–7) in vivo under non-pathological circumstances initiates
renal inflammation by activating the NF-kB pathway. This
activation by Ang-(1–7) requires Mas but does not depend on
any of the Ang II receptors.
Ang-(1–7) activates the NF-kB pathway in cultured
tubulo-epithelial cells
We performed additional in vitro studies to visualize the
postulated proinflammatory pathway stimulated by Ang-(1–7).
At first we visualized the stimulation of NF-kB translocation to the
nucleus in cultured mouse tubuloepithelial cells. In control cells a
diffuse cytoplasmic immunofluorescence was seen with antibodies
against the p65 or p50 subunits of NF-kB (Figure 5A). Treatment
with 1027 mol/L Ang-(1–7) for one hour led to an intense nuclear
fluorescence with both antibodies, proofing nuclear translocation
of NF-kB independent of the EMSA technique we used in renal
tissue (Figures 2D, 3C and 4C). Importantly, the EMSA
technique confirmed the immunofluorescence data in growth-
arrested tubuloepithelial cells. Ang-(1–7) augmented NF-kB DNA-
binding activity after 30 min being maximal with 1027 mol/L
after 1 h (P,0.05, n = 4) (Figure 5B) and diminished to control
levels at 90 min (data not shown). Notably, NF-kB activation by
Ang-(1–7) was blocked in the presence of A779 (data not
shown).
To better quantify the potency of Ang-(1–7)-mediated NF-kB
activation, we compared it to the well-known and powerful NF-
kB-activating ability of Ang II and TNFa [26]. Augmentation of
NF-kB DNA-binding activity by Ang-(1–7) was in the same range
as that for the two very potent proinflammatory factors
(Figure 5B), illustrating a possible importance of the heptapep-
tide-mediated stimulation of inflammatory processes in renal
diseases.
To evaluate whether Ang-(1–7) also regulates proinflammatory
factors under NF-kB-control under in vitro conditions, and is also
here comparably potent as TNFa, mRNA of proinflammatory
factors was quantified. Ang-(1–7) upregulated gene expression of
the cytokine IL-6 and the chemokine MCP-1 at both 18 and 24 h
(Figure 5C) and this stimulation was comparable to the one
induced by TNFa.
Discussion
Over the last decade, evidence accumulated that Ang-(1–7) has
cardiovascular protective effects [8,21,22] and counteracts detri-
mental effects of Ang II under pathophysiological conditions [30].
These effects may relate to the heptapeptide’s ability of
vasorelaxation post myocardial infarction and its blood pressure-
lowing effects under hypertensive conditions. However, all data
presented here identify Ang-(1–7) and Mas to have also significant
impact on renal inflammation and thus may have decisive
properties in the pathogenesis and progression of renal failure.
Their proinflammatory properties, being equally potent as the
stimulatory capacity of Ang II and TNFa, may counteract the
common idea of Ang-(1–7) agonists as a therapy concept in
cardiac failure.
Nevertheless Ang-(1–7) and Mas’ ability to stimulate inflamma-
tory properties in the kidneys are undoubtedly from the data
presented here. Although there were first indications for Ang-(1–7)
to have such properties, because the peptide can increase the
number of white blood cells [31,32], we were interested in
discovering more detailed mechanisms Mas and the heptapeptide
may influence inflammatory processes. The recruitment of
immune cells into the damaged kidney is a main feature of many
renal diseases. These infiltrating inflammatory cells (monocytes/
macrophages, T cells, and neutrophils) mediate the initiation and
progression of damage by direct cytotoxicity, the secretion of
soluble factors, such as proinflammatory cytokines, metalloprotei-
nases, and growth factors, which modulate the local response and
increase inflammation within the damage of kidney [33].
However, regulation renal inflammation is complex, involving
activation of transcription factors and induction of chemokines
and other proinflammatory mediators [25,34]. Our data impli-
cates that the proinflammatory properties of Ang-(1–7) and the
Mas receptor in the kidney are primarily stimulated by a local
activation of the NF-kB pathway, and the upregulation of
proinflammatory genes under its control, like MCP-1 and IL-6,
rather than by systemic effects as stimulating bone marrow-based
progenitors of inflammatory cells. This conclusion is also
supported by direct stimulating effects of the heptapeptide on
cultured renal cells to stimulate the activation of NF-kB and
related genes.
Importantly, Ang-(1–7) stimulates proinflammatory factors
independently from Ang II receptors. Furthermore, the absence
of renal Mas significantly brakes their stimulation of NF-kB and
downstream factors and blunts the stimulatory effects of Ang-(1–7).
While some experimental studies based on the interference with
chemokine expression or inhibition of NF-kB have shown
beneficial effects [18,35], under certain circumstances, this may
worsen the disease [36]. For this reason other targets are needed
for the treatment of renal diseases. Since Ang-(1–7) promotes and
Mas deficiency inhibits disease progression in two independent
experimental models, both are candidates for pharmacological
intervention.
As recent studies have demonstrated that several chronic kidney
diseases, including diabetic nephropathy can be considered as
inflammatory diseases [27,37], our data may open a new avenue
in the understanding of the genesis and disease progression due to
the identification of two new key players in renal inflammation. As
our data identify the lack/blockade of signaling of Mas as
preventing renal inflammation, it may point to unique therapy
strategies targeting the receptor and thus identified a promising
new tool in preventing or delaying inflammatory renal diseases.
Materials and Methods
Animals
Three-month old Mas-deficient mice [15] and their wild-type
controls, both on a C57Bl/6 background, were used in the
experiments. Independent sets of C57Bl/6 mice at the same age
were used for the infusion experiments (saline or Ang-(1–7).
Furthermore, mice deficient in all three Ang II receptors (AT1A,
AT1B, AT2; triple knockouts) [29] and their own wild-type
controls were used from the breeding colony of Thomas Walther
at the FEM, Berlin, Germany. All animals were maintained under
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standardized conditions with an artificial 12-h dark-light cycle,
with free access to food and water. Animals were killed by cervical
dislocation, and kidneys were immediately removed and further
processed for histological studies or frozen in liquid nitrogen for
evaluation of RNA, protein and transcription factor activity.
Control (saline-infused) animals and control animals without
surgery (sham) of the same age were used as internal controls in all
experimental settings. All animal studies were performed accord-
ing to national guidelines and approved by the institutional animal
care committees in Spain and Germany. This research was in
compliance with the Guide for the Care and Use of Laboratory
Animals published by the OPRR (Office for Protection against
Research Risks) of the US National Institutes of Health,
Washington, D.C. (NIH Publication No. 85-23, revised 1985).
Unilateral ureteral obstruction (UUO)
Mas-deficient mice (Mas2/2) and their age-matched wild-type
controls (Mas+/+) underwent UUO. Mice were anesthetized by
pentobarbital injection. The left ureter was ligated with silk (4/0)
at two locations and cut between ligatures (obstructed kidney), as
described before [18]. Contralateral kidneys served as controls.
Animals were studied for 2, 5 and 7 days (n = 6–10 animals per
genotype, per time point). Renal function was characterized as
described before by others [38].
Renal ischemia/reperfusion (I/R)
Mice were anesthetized by isoflurane inhalation. Anesthesia was
maintained using a mixture of N2O/O2/isoflurane. Normal body
temperature was maintained by placing the animals on heating
pads until recovery from anesthesia. Following a midline
abdominal incision, the left renal pedicle was localized and the
renal artery and vein were dissected. An atraumatic micro-
vascular clamp was placed, and the left kidney was occluded
during 25 minutes. After inspection for signs of ischemia, the
wound was covered with PBS soaked cotton and the animal was
covered with a tin foil insulation sheet. After release of the clamp,
restoration of blood-flow was inspected visually and a contra-
lateral nephrectomy was performed. The excised right kidney was
snap frozen and stored at 280uC for further analysis. The
abdominal wound was closed in two layers using 5/0 sutures (B.
Braun, Melsungen, Germany). The animals were given 0.5 ml
PBS subcutaneously and placed under a heating lamp to recover
from surgery.
Peptide application in UUO and I/R
Immediately following UUO or induction of renal ischemia-
reperfusion injury, groups of animals were treated with Ang-(1–7)
(15 mg/mouse per day) or saline by continuous subcutaneous
infusion using osmotic minipumps (Alza Corp., Palo Alto, CA,
USA) that were implanted between the scapula (n = 6–10 animals
per group). Since Alzet pumps have a lag time of 2 hours before
starting to release the peptide, we placed them in PBS solution
2 hours before implantation.
Systemic peptide infusion to healthy mice
The in vivo effect of Ang-(1–7) in the kidney was evaluated by
systemic infusion of Ang-(1–7) (dissolved in saline) into mice
(subcutaneously by osmotic minipumps, Alza Corp., Palo Alto,
CA, USA), at the dose of 45 mg/mouse per day. Mas-deficient
(Mas2/2), triple knockouts (TKO) and their wild-type controls
(Mas+/+, TWT) underwent infusion for 5 days (n = 6–10 animals
per group). In parallel sets, the Ang-(1–7) receptor was
pharmacologically blocked using the specific Ang-(1–7) antagonist
A779 (60 mg/mouse per day, by subcutaneous osmotic mini-
pumps), starting 24 h before Ang-(1–7) infusion and during all the
period of study (n = 6–10 animals per group). Peptides were
provided by Bachem (Weil am Rhein, Germany).
Renal histology and inflammatory cell infiltration
Paraffin sections of mouse tissues were prepared and stained
using standard histology procedures, including hematoxylin/eosin
(HE), Azan blue, Masson, Ladewig and van Gieson, as we
described before [18,39]. The protocol for periodic acid-Schiff
(PAS) staining was adapted from Padi & Chopra [40]. The slides
were deparafinized through xylene, and hydrated through graded
ethanol. Finally, they have been examined by light microscopy.
Inflammatory cell infiltration was determined by monoclonal
antibodies against F4/80 antigen (Serotec, Oxford, UK), present
in murine monocytes/macrophages. Briefly, paraffin-embedded
sections were rehydrated, their endogenous peroxidase blocked,
and incubated for 1 hour at 25uC with 8% bovine serum albumin
(BSA)/5% goat serum in phosphate-buffered saline (PBS) to
eliminate nonspecific protein binding sites. The slides were then
exposed (overnight, 4uC) to the monoclonal F4/80 antibody
(dilution 1/50). After removing excess antibody, slides were treated
with the corresponding anti-IgG biotinylated-conjugated antibody
followed by the avidin-biotin-peroxidase complex (Dako, Dako
Diagno´sticos S.A, Barcelona, Spain), and 3,39-diaminobenzidine
as chromogen. Some tissue samples were incubated without the
primary antibody or unrelated IgG, as negative controls.
One method used to quantify infiltrating cells was
image analysis using a KZ 300 imaging system 3.0 (Zeiss,
Munchen-Hallbergmoos, Germany). Briefly, the percentage of the
stained area was calculated as the ratio of stained area and the
total field area. For each sample, the mean staining area was
obtained by analysis of 10 different fields (6200). The staining
score is expressed as F4/80-positive cells/mm2. The immunohis-
tochemistry experiments were performed in two kidney sections
per experimental animal to obtain a mean score for each of them.
In all cases, evaluations were performed by two independent
observers in a blinded fashion and the mean score value calculated
for each mouse.
Stereological Analyses
The optical dissector method [41] was used to determine the
total number of inflammatory cells per kidney. All estimates were
performed using a 1006 objective on an Olympus BX-50
microscope (Tokyo, Japan). The images were captured by a JVC
TK-C1381EG (JVC, Yokohama, Japan) color video camera
coupled to a Pentium PC computer. A software program, DH
CASTGRID V1.10 (Olympus, Munich, Germany), was used to
superimpose a set of unbiased counting frames on the video image.
Fields were selected using a systematic uniform random sampling
scheme as previously described [41,42] using a computer-driven
motorized stage (Multicontrol 2000; ITK, Lahnau, Germany). A
microcator (Heidenhain D83301; Heidenhain, Traunreut, Ger-
many) was attached to the microscope stage and monitored depth
measurement.
The leukocytes were identified based on their morphology and
location within the renal cortex, medulla, and pelvis. The frame
size for counting leukocytes was 2820 mm2. On the other hand, 4
frames with a total of 940 mm2 frame size were used to count
glomerular injury (collapse, matrix deposition, thrombi). The
difference in the number of fields and frame sizes depended on the
frequency of the cells observed. Slides were masked prior to each
type of quantification (cell number and apoptosis as outlined
below) to facilitate unbiased counting.
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Cell Culture
A. Conditions. The murine tubuloepithelial cells (MCT cell
line) were kindly donated by Dr. E.G. Neilson (Pennsylvania
University, Philadelphia, PA, USA). Cells were cultured in petri-
dishes with RPMI 1640 medium (BioWhitaker, Verviers, Belgium)
supplemented with 10% fetal calf serum (FCS) and penicillin/
glutamine (Gibco BRL, Paisley, Scotland, UK).
B. Peptide treatments. MCT cells were serum-depleted for
24 h and then stimulated during 18 h or 24 h with AngII or
Ang(1–7) 1027 mol/L (Bachem, Weil am Rhein, Germany), or
TNF alpha 100 U/ml (Immunogenix corp., Los Angeles, CA,
USA) in serum-free medium.
C. Immune-fluorescence visualizing NF-kB trans-
location. Immuno-fluorescence staining for p65 and p50 was
done in MCT cells growing in coverslips. After stimulation, cells
were washed with PBS, fixed in merckofix (Merck, Darmstadt,
Germany) and treated with 0.1% Triton-X 100 for 1 minute on
ice to permeabilize nuclear membranes and blocking with 10%
sheep serum and 4% BSA in PBS for 1 hour. NF-kB subunits were
detected by rabbit polyclonal anti-p65 or p50 antibodies (1:75
dilution in 4% sheep serum and 1% BSA in PBS; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, U.S.A.) followed by FITC-
conjugated goat anti-rabbit IgG antibody (1:100 dilution in 1%
BSA in PBS). Nuclei were stained with propidium iodide (1 mg/
ml) for 30 minutes. Coverslips were mounted in mowiol
(Calbiochem, Merck KGaA. Biosciences, Darmstadt, Germany)
and examined by a laser scanning confocal microscope (Leica
Microsistemas, Alcobendas, Spain).
Quantitative real-time PCR
Total RNA was isolated with Trizol (Gibco BRL, Paisley,
Scotland, UK) with subsequent chloroform-isopropanol extraction
according to the manufacturer’s instructions. Two mg of RNA
underwent random primed reverse transcription using a modified
Maloney murine leukemia virus reverse transcriptase (Superscript
II; Life Technologies, Gaithersburg, MD, USA) for 10 minutes at
25uC and 37uC for 2 hours. Proinflammatory gene expression was
analyzed by real-time PCR, performed on an ABI Prism 7500
sequence detection PCR system (Applied Biosystems, Foster City,
CA, USA) according to manufacturer’s protocol. After an initial
hold of 2 minutes at 50uC and 10 minutes at 95uC, the samples
were cycled 40 times at 95uC for 15 seconds and 60uC for
60 seconds. For all quantitative cDNA analysis, the DCt technique
was applied. Assay IDs used were MCP-1, Mm00441242_m1 and
IL-6, Mm00446190_m1. To normalize data different approaches
were done using several housekeeping genes, including GAPDH,
Histone-3 and 18 s ribosomal RNA expression (assay IDs:
Mm99999915_g1 and Hs99999901_s). All primers, probes, and
reagents were obtained from Applied Biosystems (Foster City, CA,
USA). All measurements were performed in duplicate. Controls
consisting of ddH2O were negative in all runs.
Determination of NF-kB activity with electrophoretic
mobility shift assay (EMSA)
A. Protein extraction. For protein extraction from tissues,
frozen kidney pieces were pulverized in a metallic chamber and
resuspended in a cold extraction buffer [20 mmol/L HEPES-
NaOH (pH 7.6), 20% (vol-vol) glycerol, 0.35 mol/L NaCl,
5 mmol/L MgCl2, 0.1 mmol/L EDTA, 1 mmol/L DTT,
0.5 mmol/L PMSF]. The homogenate was vigorously shaken for
30 minutes, and the insoluble materials precipitated by
centrifugation at 40,000 g for 30 minutes at 4uC. For protein
extraction from cultured cells, cells were resuspended in extraction
buffer (10 mmol/L HEPES, pH 7.8, 15 mmol/L KCl, 2 mmol/L
MgCl2, 0.1 mmol/L EDTA, 1 mmol/L dithiothreitol, 1 mmol/L
PMSF) and homogenized. Nuclei and cytosolic fractions were
separated by centrifugation at 1,0006g for 10 minutes. The nuclei
were resuspended in extraction buffer to a final concentration of
0.39 mol/L KCl and centrifuged at 100,0006g for 30 minutes.
Supernatants dialyzed overnight against a binding buffer
containing 20 mmol/L HEPES-NaOH (pH 7.6), 20% (v/v)
glycerol, 0.1 mmol/L NaCl, 5 mmol/L MgCl2, 0.1 mmol/L
EDTA, 1 mmol/L dithiothreitol, and 0.5 mmol/L PMSF. The
dialysates were cleared by centrifugation at 10,0006g for
15 minutes at 4uC and frozen at 280uC. Protein concentration
was quantified by the bicinchoninic acid method (Pierce,
Rockford, IL, USA).
B. Electrophoretic mobility shift assay. NF-kBactivitywas
evaluated by binding of 60 mg of tissue extracts of tissue or 8–10 mg of
nuclear extracts from cells, as described [18]. NF-kB consensus
oligonucleotide (59-AGTTGAGGGGACTTTCCCAGGC-39) was
end-labeled with [c-32P]-ATP (Amersham, Buckinghamshire, UK)
and T4 polynucleotide kinase (Promega, Madison, WI, USA).
Samples were equilibrated for 10 minutes in a binding buffer [4%
glycerol, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 0.5 mmol/L
dithiothreitol, 50 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 7.5,
and 50 mg/ml of poly(dI-dC)] (Pharmacia LKB, Uppsala, Sweden),
then the NF-kB consensus oligonucleotide labeled [c-32P]-ATP
(0.35 pmol) was added and incubated for 20 minutes at room
temperature.
Negative controls without cellular extracts, and competition
assays with a 100-fold excess of unlabeled NF-kB, mutant NF-kB
and AP-1 (unrelated) oligonucleotides, were performed to establish
the specificity of the reaction (not shown). When competition
assays were done, the unlabeled probe was added to this buffer
10 minutes prior to the addition of the labeled probe. The results
of EMSA experiments were analyzed using a Densitometer (GS-
800, Biorad, Alcobendas, Madrid, Spain). The specificity of the
antibodies was confirmed by Western blot. Oligonucleotides were
from Promega Corp. (Madison, WI, USA). The reaction was
stopped by adding gel-loading buffer (250 mmol/L Tris-HCL,
0.2% bromophenol blue, 0.2% xylene cyanol, and 40% glycerol)
and protein-DNA complexes were separated on a nondenaturing,
4% acrylamide gel in Tris-borate. The gels were dried and
exposed to X-ray film.
Western blot analysis
Protein levels were assessed by Western blotting. Total proteins
were resolved on 12% sodium dodecyl sulfate-polyacrylamide gels,
electrophoretically transferred to polyvinylidene difluoride mem-
branes, blocked (in buffer containing 0.01 mM Tris, pH 7.5,
0.4 M NaCl, 0.1% Tween-20, 1% bovine serum albumin, and 5%
milk), and incubated for 18 h at 4uC with Bax and Bcl-xL
antibodies (1:1000 and 1:500, respectively) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Detection was performed with
peroxidase-conjugated secondary antibody, using an ECL chemi-
luminescence kit (Amersham, Arlington Heights, IL, USA).
Statistical analysis
Since all investigated parameters were normally distributed
having continuous variables with equal variances, we analyzed
with student t test or ANOVA. For UUO, all parameters
investigated did not differ between contralateral kidneys and
kidneys from control mice (without surgery) in each genotype
studied (data not shown). Data are expressed as mean6SEM. A
P,0.05 was considered significant. Tests were done using the
SPSS 11.5 software package.
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